Connection

JEFFREY E GERSHENWALD to Male

This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Male.
Connection Strength

0.565
  1. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835.
    View in: PubMed
    Score: 0.019
  2. Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. J Natl Cancer Inst. 2016 Jan; 108(1).
    View in: PubMed
    Score: 0.016
  3. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med. 2014 Feb 13; 370(7):663-4.
    View in: PubMed
    Score: 0.014
  4. Randomized controlled trial of a sun protection intervention for children of melanoma survivors. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1813-24.
    View in: PubMed
    Score: 0.014
  5. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008 Sep 10; 26(26):4296-303.
    View in: PubMed
    Score: 0.009
  6. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006 Dec 01; 107(11):2647-52.
    View in: PubMed
    Score: 0.008
  7. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol. 2006 Jul; 187(1):W117-9.
    View in: PubMed
    Score: 0.008
  8. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006 Feb 15; 106(4):900-6.
    View in: PubMed
    Score: 0.008
  9. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005 Aug; 12(8):587-96.
    View in: PubMed
    Score: 0.008
  10. Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. J Cutan Pathol. 2024 Sep; 51(9):644-648.
    View in: PubMed
    Score: 0.007
  11. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol. 2023 10 01; 159(10):1076-1084.
    View in: PubMed
    Score: 0.007
  12. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol. 2023 11; 188:109892.
    View in: PubMed
    Score: 0.007
  13. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003 Jun; 10(5):569-74.
    View in: PubMed
    Score: 0.007
  14. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022 11; 23(11):1378-1388.
    View in: PubMed
    Score: 0.006
  15. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg. 2022 09 01; 157(9):835-842.
    View in: PubMed
    Score: 0.006
  16. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002 Jul 15; 95(2):354-60.
    View in: PubMed
    Score: 0.006
  17. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.006
  18. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.006
  19. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol. 2022 Mar; 125(4):719-729.
    View in: PubMed
    Score: 0.006
  20. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001 Nov; 108(11):2101-5.
    View in: PubMed
    Score: 0.006
  21. Sentinel lymph node biopsy for conjunctival melanoma. Ophthalmic Plast Reconstr Surg. 2001 Nov; 17(6):436-42.
    View in: PubMed
    Score: 0.006
  22. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene. 2001 Jun 07; 20(26):3363-75.
    View in: PubMed
    Score: 0.006
  23. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? Surgery. 2000 Aug; 128(2):306-11.
    View in: PubMed
    Score: 0.005
  24. Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2000 May; 7(4):256-61.
    View in: PubMed
    Score: 0.005
  25. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol. 2000 Apr; 7(3):226-31.
    View in: PubMed
    Score: 0.005
  26. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000 Mar; 7(2):160-5.
    View in: PubMed
    Score: 0.005
  27. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.
    View in: PubMed
    Score: 0.005
  28. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.005
  29. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020 01 14; 30(2):510-524.e6.
    View in: PubMed
    Score: 0.005
  30. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
    View in: PubMed
    Score: 0.005
  31. Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. J Natl Cancer Inst. 2019 12 01; 111(12):1314-1322.
    View in: PubMed
    Score: 0.005
  32. Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. Cancer. 2020 02 15; 126(4):775-781.
    View in: PubMed
    Score: 0.005
  33. Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593.
    View in: PubMed
    Score: 0.005
  34. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.005
  35. Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol. 2019 11; 139(11):2352-2358.e3.
    View in: PubMed
    Score: 0.005
  36. Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. Ann Surg Oncol. 2019 Sep; 26(9):2667-2674.
    View in: PubMed
    Score: 0.005
  37. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999 Mar; 17(3):976-83.
    View in: PubMed
    Score: 0.005
  38. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.005
  39. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.
    View in: PubMed
    Score: 0.005
  40. A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. J Surg Oncol. 2018 Nov; 118(6):922-927.
    View in: PubMed
    Score: 0.005
  41. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res. 2018 10 01; 78(19):5680-5693.
    View in: PubMed
    Score: 0.005
  42. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998 Aug; 124(2):203-10.
    View in: PubMed
    Score: 0.005
  43. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.
    View in: PubMed
    Score: 0.005
  44. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.005
  45. Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res. 2018 09 01; 24(17):4119-4125.
    View in: PubMed
    Score: 0.005
  46. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Med. 2018 03; 7(3):583-593.
    View in: PubMed
    Score: 0.005
  47. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.005
  48. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 06 08; 376(23):2211-2222.
    View in: PubMed
    Score: 0.004
  49. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.
    View in: PubMed
    Score: 0.004
  50. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
    View in: PubMed
    Score: 0.004
  51. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.004
  52. Melanoma Expression Genes Identified through Genome-Wide Association Study of?Breslow Tumor Thickness. J Invest Dermatol. 2017 01; 137(1):253-257.
    View in: PubMed
    Score: 0.004
  53. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J Natl Cancer Inst. 2016 09; 108(9).
    View in: PubMed
    Score: 0.004
  54. Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US?Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol. 2016 09; 136(9):1894-1897.
    View in: PubMed
    Score: 0.004
  55. Correlates of Sun Protection and Sunburn in Children of Melanoma Survivors. Am J Prev Med. 2016 09; 51(3):e77-85.
    View in: PubMed
    Score: 0.004
  56. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7.
    View in: PubMed
    Score: 0.004
  57. Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore). 2016 Mar; 95(11):e3073.
    View in: PubMed
    Score: 0.004
  58. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol. 2016 Apr 01; 34(10):1079-86.
    View in: PubMed
    Score: 0.004
  59. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.
    View in: PubMed
    Score: 0.004
  60. CDC Grand Rounds: Prevention and Control of Skin Cancer. MMWR Morb Mortal Wkly Rep. 2015 Dec 04; 64(47):1312-4.
    View in: PubMed
    Score: 0.004
  61. The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. J Surg Oncol. 2015 Dec; 112(8):834-40.
    View in: PubMed
    Score: 0.004
  62. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.004
  63. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol. 2015 Sep; 135(9):2266-2272.
    View in: PubMed
    Score: 0.004
  64. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl). 2015 Sep; 24(5):724-33.
    View in: PubMed
    Score: 0.004
  65. C-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015 Apr 20; 33(12):1389-96.
    View in: PubMed
    Score: 0.004
  66. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer. 2015 Apr 15; 136(8):1874-80.
    View in: PubMed
    Score: 0.004
  67. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.004
  68. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014 Jun; 259(6):1215-22.
    View in: PubMed
    Score: 0.004
  69. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
    View in: PubMed
    Score: 0.003
  70. Relationships among primary tumor size, number of?involved nodes, and survival for 8044 cases of?Merkel cell carcinoma. J Am Acad Dermatol. 2014 Apr; 70(4):637-643.
    View in: PubMed
    Score: 0.003
  71. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.
    View in: PubMed
    Score: 0.003
  72. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013 Nov 01; 119(21):3821-9.
    View in: PubMed
    Score: 0.003
  73. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res. 2013 Aug; 23(4):290-7.
    View in: PubMed
    Score: 0.003
  74. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
    View in: PubMed
    Score: 0.003
  75. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013 Jul 01; 19(13):3611-20.
    View in: PubMed
    Score: 0.003
  76. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol. 2013 Jul; 133(7):1813-21.
    View in: PubMed
    Score: 0.003
  77. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
    View in: PubMed
    Score: 0.003
  78. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75.
    View in: PubMed
    Score: 0.003
  79. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44.
    View in: PubMed
    Score: 0.003
  80. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012 Apr; 214(4):608-17; discussion 617-9.
    View in: PubMed
    Score: 0.003
  81. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health. 2011 Sep-Oct; 14(6):900-6.
    View in: PubMed
    Score: 0.003
  82. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011 Dec; 18(13):3593-600.
    View in: PubMed
    Score: 0.003
  83. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg. 2011 Jun; 253(6):1211-5.
    View in: PubMed
    Score: 0.003
  84. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
    View in: PubMed
    Score: 0.003
  85. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol. 2011 Mar; 66(3):224-36.
    View in: PubMed
    Score: 0.003
  86. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15.
    View in: PubMed
    Score: 0.003
  87. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010 Nov; 63(5):751-61.
    View in: PubMed
    Score: 0.003
  88. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010 May 01; 116(9):2234-41.
    View in: PubMed
    Score: 0.003
  89. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010 Aug; 17(8):2006-14.
    View in: PubMed
    Score: 0.003
  90. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol. 2010 Aug; 17(8):2015-23.
    View in: PubMed
    Score: 0.003
  91. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
    View in: PubMed
    Score: 0.003
  92. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010 Oct; 17(10):2764-72.
    View in: PubMed
    Score: 0.003
  93. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010 Mar; 17(3):709-17.
    View in: PubMed
    Score: 0.003
  94. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
    View in: PubMed
    Score: 0.003
  95. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009 Jun 01; 115(11):2505-13.
    View in: PubMed
    Score: 0.003
  96. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.002
  97. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1376-82.
    View in: PubMed
    Score: 0.002
  98. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40.
    View in: PubMed
    Score: 0.002
  99. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol. 2008 Jun 18; 6:63.
    View in: PubMed
    Score: 0.002
  100. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008 May 15; 112(10):2249-57.
    View in: PubMed
    Score: 0.002
  101. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84.
    View in: PubMed
    Score: 0.002
  102. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7.
    View in: PubMed
    Score: 0.002
  103. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008 Mar; 195(3):363-8; discussion 368-9.
    View in: PubMed
    Score: 0.002
  104. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8.
    View in: PubMed
    Score: 0.002
  105. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007 Oct; 14(10):2867-75.
    View in: PubMed
    Score: 0.002
  106. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8.
    View in: PubMed
    Score: 0.002
  107. Segmental neurofibromatosis in association with a large congenital nevus and malignant melanoma. Dermatol Online J. 2006 Dec 10; 12(7):22.
    View in: PubMed
    Score: 0.002
  108. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32.
    View in: PubMed
    Score: 0.002
  109. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006 Sep 25; 166(17):1907-14.
    View in: PubMed
    Score: 0.002
  110. Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia. 2006 Sep; 8(9):747-57.
    View in: PubMed
    Score: 0.002
  111. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20; 24(18):2858-65.
    View in: PubMed
    Score: 0.002
  112. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006 Jul; 13(7):902-9.
    View in: PubMed
    Score: 0.002
  113. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20.
    View in: PubMed
    Score: 0.002
  114. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901.
    View in: PubMed
    Score: 0.002
  115. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006 Jun; 13(6):809-16.
    View in: PubMed
    Score: 0.002
  116. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63.
    View in: PubMed
    Score: 0.002
  117. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006 Apr; 132(4):370-3.
    View in: PubMed
    Score: 0.002
  118. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006 May; 13(5):712-20.
    View in: PubMed
    Score: 0.002
  119. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.
    View in: PubMed
    Score: 0.002
  120. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):106-13.
    View in: PubMed
    Score: 0.002
  121. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005 Sep 01; 23(25):6054-62.
    View in: PubMed
    Score: 0.002
  122. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005 Aug; 27(8):718-21.
    View in: PubMed
    Score: 0.002
  123. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004 Dec; 11(12):1079-84.
    View in: PubMed
    Score: 0.002
  124. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth. 2004 Aug; 16(5):332-41.
    View in: PubMed
    Score: 0.002
  125. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004 Jul 01; 86(4):212-23.
    View in: PubMed
    Score: 0.002
  126. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 01; 100(7):1478-83.
    View in: PubMed
    Score: 0.002
  127. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004 Jan 15; 100(2):383-9.
    View in: PubMed
    Score: 0.002
  128. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol. 2003 Dec; 121(6):1510-4.
    View in: PubMed
    Score: 0.002
  129. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Res. 2003 Aug; 13(4):379-87.
    View in: PubMed
    Score: 0.002
  130. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol. 2003 May; 10(4):348-54.
    View in: PubMed
    Score: 0.002
  131. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003 Apr 01; 97(7):1789-96.
    View in: PubMed
    Score: 0.002
  132. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthalmic Plast Reconstr Surg. 2003 Mar; 19(2):102-6.
    View in: PubMed
    Score: 0.002
  133. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15.
    View in: PubMed
    Score: 0.002
  134. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002 Dec 01; 20(23):4555-8.
    View in: PubMed
    Score: 0.002
  135. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1142-3.
    View in: PubMed
    Score: 0.002
  136. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93.
    View in: PubMed
    Score: 0.002
  137. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70.
    View in: PubMed
    Score: 0.001
  138. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
    View in: PubMed
    Score: 0.001
  139. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001 Apr; 8(3):192-7.
    View in: PubMed
    Score: 0.001
  140. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol. 2001 Mar; 8(2):116-22.
    View in: PubMed
    Score: 0.001
  141. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem. 1998 Jun 26; 273(26):16501-8.
    View in: PubMed
    Score: 0.001
  142. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998 Jun; 5(4):322-8.
    View in: PubMed
    Score: 0.001
  143. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 1997 Oct; 151(4):1105-13.
    View in: PubMed
    Score: 0.001
  144. Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. J Infect Dis. 1992 May; 165(5):859-64.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.